Zuraw Bruce L
Veterans Affairs Medical Center, San Diego, California, USA.
Ann Allergy Asthma Immunol. 2008 Jan;100(1 Suppl 2):S13-8. doi: 10.1016/s1081-1206(10)60581-9.
To provide a context to understand the opportunity for novel therapeutic modalities to transform the treatment of hereditary angioedema (HAE).
MEDLINE and PubMed were searched to identify studies involving current treatment of HAE in the United States.
Studies were selected based on their relevance to the treatment of HAE.
The current HAE treatment strategy is far from satisfactory, and its limitations create an unmet clinical need. Current prophylactic treatment exposes patients with HAE to significant risk of adverse effects, and the efficacy of prophylactic treatment, although generally good, is far from perfect.
No specific treatment is currently available in the United States for acute HAE attacks that will reliably work, resulting in a significant unmet clinical need. The emergence of several promising drugs for the treatment of HAE attacks is, thus, an extraordinarily important development in the management of these patients.
提供一个背景，以理解新型治疗方式改变遗传性血管性水肿（HAE）治疗的机会。
检索MEDLINE和PubMed以识别涉及美国HAE当前治疗的研究。
根据与HAE治疗的相关性选择研究。
当前的HAE治疗策略远不能令人满意，其局限性造成了未满足的临床需求。当前的预防性治疗使HAE患者面临显著的不良反应风险，并且预防性治疗的疗效虽然总体良好，但远非完美。
目前美国尚无可靠有效的针对急性HAE发作的特异性治疗方法，导致了显著的未满足临床需求。因此，几种有前景的用于治疗HAE发作的药物的出现，在这些患者的管理中是一个极其重要的进展。
